Addressing the Challenges of Low Clearance in Drug Research

AAPS Journal

Volumn 17, Issue 2, 2015, Pages 352-357

  Di, Li ^a   Obach, R Scott ^a  

^a PFIZER INC   (United States)

Author keywords

hepatocyte coculture; hepatocyte relay; IVIVC; low clearance; metabolite formation; qNMR

Indexed keywords

DRUG;

ANIMAL; COCULTURE; DRUG DESIGN; DRUG DEVELOPMENT; HALF LIFE TIME; HIGH THROUGHPUT SCREENING; HUMAN; LIVER CELL; METABOLISM; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PHARMACOKINETICS; PROCEDURES;

ANIMALS; COCULTURE TECHNIQUES; DRUG DESIGN; DRUG DISCOVERY; HALF-LIFE; HEPATOCYTES; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS;

EID: 84934917121     PISSN: None     EISSN: 15507416     Source Type: Journal    
DOI: 10.1208/s12248-014-9691-7     Document Type: Article

References (22)

1. Roffey SJ, Obach RS, Gedge JI, Smith DA. What is the objective of the mass balance study? A retrospective analysis of data in animal and human excretion studies employing radiolabeled drugs. Drug Metab Rev. 2007;39(1):17–43.
2. Di L, Kerns EH, Ma XJ, Huang Y, Carter GT. Applications of high throughput microsomal stability assay in drug discovery. Comb Chem High Throughput Screen. 2008;11(6):469–76.
3. Hop CECA, Cole MJ, Davidson RE, Duignan DB, Federico J, Janiszewski JS, et al. High throughput ADME screening: practical considerations, impact on the portfolio and enabler of in silico ADME models. Curr Drug Metab. 2008;9(9):847–53.
4. Rudewicz PJ, Yue Q, Shin Y. High-throughput strategies for metabolite identification in drug discovery. High-Throughput Analysis in the Pharmaceutical Industry. 2009;141–54
5. Di L, Kerns EH, Carter GT. Drug-like property concepts in pharmaceutical design. Curr Pharm Des. 2009;15(19):2184–94.
6. Kerns EH, Di L. Drug-like properties: concepts, structure design and methods: from ADME to toxicity optimization. London: ELSEVIER; 2008.
7. Pfefferkorn JA, Guzman-Perez A, Litchfield J, Aiello R, Treadway JL, Pettersen J, et al. Discovery of (S)-6-(3-cyclopentyl-2-(4-(trifluoromethyl)-1H-imidazol-1-yl)propanamido)nicotinic acid as a hepatoselective glucokinase activator clinical candidate for treating Type 2 diabetes mellitus. J Med Chem. 2012;55(3):1318–33.
8. Oballa RM, Belair L, Black WC, Bleasby K, Chan CC, Desroches C, et al. Development of a liver-targeted stearoyl-CoA desaturase (SCD) inhibitor (MK-8245) to establish a therapeutic window for the treatment of diabetes and dyslipidemia. J Med Chem. 2011;54(14):5082–96.
9. Tu M, Mathiowetz AM, Pfefferkorn JA, Cameron KO, Dow RL, Litchfield J, et al. Medicinal chemistry design principles for liver targeting through OATP transporters. Curr Topic Med Chem (Sharjah, United Arab Emirates). 2013;13(7):857–66.
10. Rangan S, Tahrani AA, Macleod AF, Moulik PK. Once weekly thyroxine treatment as a strategy to treat non-compliance. Shrewsbury: England: United Kingdom FIELD Citation: Department of Diabetes and Endocrinology, Royal Shrewsbury Hospital; 2007. 1469–0756.
11. Jones HM, Houston JB. Substrate depletion approach for determining in vitro metabolic clearance: time dependencies in hepatocyte and microsomal incubations. Drug Metab Dispos. 2004;32(9):973–82.
12. Di L, Trapa P, Obach RS, Atkinson K, Bi Y-A, Wolford AC, et al. A novel relay method for determining low-clearance values. Drug Metab Dispos. 2012;40(9):1860–5.
13. Di L, Atkinson K, Orozco CC, Funk C, Zhang H, McDonald TS, et al. In vitro-in vivo correlation for low-clearance compounds using hepatocyte relay method. Drug Metab Dispos. 2013;41(12):2018–23.
14. Ballard TE, Orozco CC, Obach RS. Generation of major human excretory and circulating drug metabolites using a hepatocyte relay method. Drug Metab Dispos. 2014;42(5):899–902. 4pp.
15. Walker GS, Bauman JN, Ryder TF, Smith EB, Spracklin DK, Obach RS. Biosynthesis of drug metabolites and quantitation using NMR spectroscopy for use in pharmacologic and drug metabolism studies. Drug Metab Dispos. 2014;42(10):1627–39.
16. Vishwanathan K, Babalola K, Wang J, Espina R, Yu L, Adedoyin A, et al. Obtaining exposures of metabolites in preclinical species through plasma pooling and quantitative NMR: addressing metabolites in safety testing (MIST) guidance without using radiolabeled compounds and chemically synthesized metabolite standards. Chem Res Toxicol. 2009;22(2):311–22.
17. Walker GS, Ryder TF, Sharma R, Smith EB, Freund A. Validation of isolated metabolites from drug metabolism studies as analytical standards by quantitative NMR. Drug Metab Dispos. 2011;39(3):433–40.
18. Dash A, Inman W, Hoffmaster K, Sevidal S, Kelly J, Obach RS, et al. Liver tissue engineering in the evaluation of drug safety. Expert Opin Drug Metab Toxicol. 2009;5(10):1159–74.
19. Sevidal S, Kelly JM, Obach RS. The Use of a 3D Hepatic Culture System (Liverchip) as a Tool for Predicting Human Intrinsic Clearance. ISSX2008.
20. Vivares A, Salle-Lefort S, Arabeyre-Fabre C, Ngo R, Penarier G, Bremond M, et al. Morphological behaviour and metabolic capacity of cryopreserved human primary hepatocytes cultivated in a perfused multiwell device. Xenobiotica. 2014;1–16.
21. Novik E, Maguire TJ, Chao P, Cheng KC, Yarmush ML. A microfluidic hepatic coculture platform for cell-based drug metabolism studies. Biochem Pharmacol. 2010;79(7):1036–44.
22. Chan TS, Yu H, Moore A, Khetani SR, Tweedie D. Meeting the challenge of predicting hepatic clearance of compounds slowly metabolized by cytochrome P450 using a novel hepatocyte model. HepatoPac Drug Metab Dispos. 2013;41(12):2024–32.